Pharmacokinetics, Pharmacodynamics, and Safety of Nivolumab in Patients With Sepsis-Induced Immunosuppression: A Multicenter, Open-Label Phase 1/2 Study.
Journal Information
Full Title: Shock
Abbreviation: Shock
Country: Unknown
Publisher: Unknown
Language: N/A
Publication Details
Subject Category: Vascular Diseases
Available in Europe PMC: Yes
Available in PMC: Yes
PDF Available: No
Related Papers from Same Journal
Transparency Score
Transparency Indicators
Click on green indicators to view evidence textCore Indicators
"The authors report no conflicts of interest."
"This study was funded by Ono Pharmaceutical Co, Ltd and Bristol-Myers Squibb. Ono Pharmaceutical Co, Ltd was involved in the design of the study; collection, analysis, and interpretation of data; and in drafting the manuscript. Bristol-Myers Squibb did not have a role in the study design; data collection, analysis and interpretation; nor writing of the manuscript."
"Trial registration: JAPIC, JapicCTI-173600."
Additional Indicators
Assessment Info
Tool: rtransparent
OST Version: N/A
Last Updated: Aug 05, 2025